Mercer Global Advisors
BCAX

Mercer Global Advisors’s Bicara Therapeutics BCAX Stock Holding History

Mercer Global Advisors’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$101K Buy
+3,411
New +$76.1K ﹤0.01% 3834

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM

Mercer Global Advisors's BCAX Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Bicara Therapeutics (BCAX) in Q2 2026: 3,411 shares worth $101K. The stake represents ﹤0.01% of the portfolio and ranks #3834 among its holdings.

157 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Mercer Global Advisors held 3,411 shares of Bicara Therapeutics worth $101K as of Q2 2026.
  • Bicara Therapeutics was a new Mercer Global Advisors position in Q2 2026.
  • Bicara Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #3834 holding.
  • 157 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.